Trial Profile
A Phase I, Safety, Tolerability, and Pharmacokinetic Interaction Study of Single-Dose TMC207 and Efavirenz in Healthy Volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Bedaquiline (Primary) ; Efavirenz
- Indications HIV infections; Tuberculosis
- Focus Adverse reactions; Pharmacokinetics
- 27 Apr 2012 Actual end date changed from Jul 2011 to Dec 2010 as reported by ClinicalTrials.gov.
- 24 Feb 2012 Actual patient number is 37 according to ClinicalTrials.gov.
- 24 Feb 2012 Actual end date changed from Dec 2010 to 1 Jul 2011 as reported by ClinicalTrials.gov.